191 related articles for article (PubMed ID: 11771732)
21. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol.
Sasaki K; Hayashi K; Matsuya Y; Sugimoto K; Lee JB; Kurosaki F; Hayashi T
J Nat Med; 2016 Apr; 70(2):217-24. PubMed ID: 26763002
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man.
Henao-Martínez AF; Weinberg A; Waldman WJ; Levi ME
J Clin Virol; 2012 Jul; 54(3):276-8. PubMed ID: 22465339
[TBL] [Abstract][Full Text] [Related]
24. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
Fuchs J; Celum C; Wang J; Hughes J; Sanchez J; Cowan F; Reid S; Delany-Moretlwe S; Corey L; Wald A;
J Infect Dis; 2010 Apr; 201(8):1164-8. PubMed ID: 20214474
[TBL] [Abstract][Full Text] [Related]
25. Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
Safrin S; Kemmerly S; Plotkin B; Smith T; Weissbach N; De Veranez D; Phan LD; Cohn D
J Infect Dis; 1994 Jan; 169(1):193-6. PubMed ID: 8277181
[TBL] [Abstract][Full Text] [Related]
26. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.
Pyles RB; Higgins D; Chalk C; Zalar A; Eiden J; Brown C; Van Nest G; Stanberry LR
J Virol; 2002 Nov; 76(22):11387-96. PubMed ID: 12388699
[TBL] [Abstract][Full Text] [Related]
27. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
28. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
[TBL] [Abstract][Full Text] [Related]
29. Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity.
Lehrman SN; Douglas JM; Corey L; Barry DW
Ann Intern Med; 1986 Jun; 104(6):786-90. PubMed ID: 3010782
[TBL] [Abstract][Full Text] [Related]
30. Antiviral susceptibility of Herpes simplex viruses and its clinical correlates: a single center's experience.
Rabella N; Otegui M; Labeaga R; Rodríguez P; Margall N; Gurguí M; Prats G
Clin Infect Dis; 2002 Apr; 34(8):1055-60. PubMed ID: 11914993
[TBL] [Abstract][Full Text] [Related]
31. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women.
Gupta R; Hill EL; McClernon D; Davis G; Selke S; Corey L; Wald A
J Infect Dis; 2005 Sep; 192(6):1102-7. PubMed ID: 16107966
[TBL] [Abstract][Full Text] [Related]
32. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.
Wald A; Zeh J; Barnum G; Davis LG; Corey L
Ann Intern Med; 1996 Jan; 124(1 Pt 1):8-15. PubMed ID: 7503497
[TBL] [Abstract][Full Text] [Related]
33. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time.
Benedetti JK; Zeh J; Corey L
Ann Intern Med; 1999 Jul; 131(1):14-20. PubMed ID: 10391810
[TBL] [Abstract][Full Text] [Related]
34. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
35. Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.
Eide K; Moerdyk-Schauwecker M; Stein DA; Bildfell R; Koelle DM; Jin L
Antivir Ther; 2010; 15(8):1141-9. PubMed ID: 21149921
[TBL] [Abstract][Full Text] [Related]
36. The synergistic effects of betulin with acyclovir against herpes simplex viruses.
Gong Y; Raj KM; Luscombe CA; Gadawski I; Tam T; Chu J; Gibson D; Carlson R; Sacks SL
Antiviral Res; 2004 Nov; 64(2):127-30. PubMed ID: 15498608
[TBL] [Abstract][Full Text] [Related]
37. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient.
Cury K; Valin N; Gozlan J; Jacquier I; Boutolleau D; Guegan S; Flejou JF; Girard PM
Sex Transm Dis; 2010 Feb; 37(2):126-8. PubMed ID: 19858782
[TBL] [Abstract][Full Text] [Related]
38. Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate.
Oram RJ; Marcellino D; Strauss D; Gustafson E; Talarico CL; Root AK; Sharma PL; Thompson K; Fingeroth JD; Crumpacker C; Herold BC
J Infect Dis; 2000 Apr; 181(4):1458-61. PubMed ID: 10762577
[TBL] [Abstract][Full Text] [Related]
39. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.
van Velzen M; van de Vijver DA; van Loenen FB; Osterhaus AD; Remeijer L; Verjans GM
J Infect Dis; 2013 Nov; 208(9):1359-65. PubMed ID: 23901090
[TBL] [Abstract][Full Text] [Related]
40. Acyclovir resistant genital herpes virus infection in a patient with AIDS.
Marrero M; Alvarez M; Millan JC; Mas Lago P; Soler M; Diaz M
Acta Virol; 1991 Jan; 35(1):86-9. PubMed ID: 1683121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
